{"entity":{"id":"nct06220318","kind":"trial","name":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Sintilimab in advanced solid tumours, run by Fujian Haixi Pharmaceuticals Co., Ltd., active and no longer recruiting.","summary":"Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06220318 by Fujian Haixi Pharmaceuticals Co., Ltd., with 155 participants enrolled, started 2023-07-19 and due to reach its primary completion in 2026-08-30. Interventions recorded: C019199 and Sintilimab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06220318","url":"https://clinicaltrials.gov/study/NCT06220318"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sintilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06220318","phase":"1/2","setting":"A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors","sponsor":"Fujian Haixi Pharmaceuticals Co., Ltd.","enrolled":155,"outcomes":[]},"route":"/trials/nct06220318/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}]}}